Findings identify bromophenyl-substituted imidazolone derivatives, particularly compound 5, as promising anticancer lead candidates, while suggesting EGFR as a plausible molecular target.
Abstract
A series of novel bromophenyl-substituted imidazolone derivatives were synthesized from (Z)-4-(2-bromobenzylidene)-2-phenyloxazol-5(4H)-one through reactions with various nitrogen nucleophiles. The antiproliferative activities of the synthesized candidates were evaluated against HepG-2 (liver), MCF-7 (breast), and HCT-116 (colon) human cancer cell lines, together with normal WI-38 fibroblasts. Among the tested candidates, the carboethoxy-substituted imidazolone derivative 5 exhibited the most promising anticancer activity, displaying IC50 values of 9.52, 12.39, and 7.32 µM against HepG-2, MCF-7, and HCT-116 cells, respectively, with a good selectivity index (SI = 7.2), markedly exceeding that of doxorubicin. Compound 2 also demonstrated potent cytotoxicity against HepG2 and MCF-7 cells with favorable selectivity. In silico ADME evaluation demonstrated that the majority of the synthesized derivatives complied with Lipinski's Rule of Five and Veber's guidelines, indicating promising oral bioavailability and favorable pharmacokinetic characteristics. Molecular docking studies against epidermal growth factor receptor tyrosine kinase (EGFR-TK, PDB ID: 6V5N) revealed strong binding affinities for the active derivatives, with imidazolone 5 exhibiting the highest docking score (−8.035 kcal mol−1) and forming key interactions with important residues, including LYS745, ASP855, and ARG841. Frontier molecular orbital and molecular electrostatic potential analyses further supported the observed biological activities by revealing favorable electronic properties and reactive sites. Collectively, these findings identify bromophenyl-substituted imidazolone derivatives, particularly compound 5, as promising anticancer lead candidates, while suggesting EGFR as a plausible molecular target.
Findings highlight compound 5d as a promising lead candidate for further optimization and cellular mechanistic validation in anti-cancer drug discovery.
M. Sarg, Fatma G. Abdulrahman, Yasmin S. Sheta et al.· Bioorganic & Medicinal Chemi...· 0 citations
A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.
Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al.· Bioorganic chemistry (Print)· 0 citations
The synthesized benzoxazole hybrid compounds showed promising anticancer activity with acceptable ADMET properties; however, further structural optimization and mechanistic studies are needed to validate the molecular targets and improve safety and pharmacokinetic profiles.
Mahmoud A. Al-Sha'er, A. H. Abdullah, Almeqdad Y. Habashneh et al.· Chemistry Africa· 0 citations
The synthesis of a number of novel pyridine/thiazole hybrids 1 to 6a,b and their screening as possible anticancer drugs through dual targeting of VEGFR-2 and EGFR are highlighted and every synthesized compound demonstrated minimal toxicity toward VERO normal cells.
N. Ahmed, Rizk E. Khidre, Mohamed R. Khidre et al.· Bioorganic chemistry (Print)· 0 citations
This study provides integrated experimental and computational insights into the anticancer potential of tosylate-bearing heterocyclic scaffolds, addressing gaps in understanding their structure–activity relationships.
Gehad E. Said, Sonia Samy, E. Abdel-Galil et al.· RSC Advances· 0 citations
INTRODUCTION
EF24, a synthetic curcumin derivative, is effective against different forms of cancers but its derivatives are underdeveloped, particularly to improve cytotoxicity and drug-receptor interactions in colorectal cancer.
AREAS COVERED
Nine N-benzoyl EF24 analogs were prepared and identified by Fourier transf...
Fatemeh Khademi Moughari, Ramin Ebrahimi Kiasari, G. Ghavami et al.· Future Medicinal Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.